Clinical Trial Update: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 study comparing Sirukumab monotherapy to Adalimumab monotherapy in active rheumatoid arthritis has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)
• Sirukumab (sirukumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2017-09-14